Interleukin 35 Protein (IL35) (AA 21-229, AA 57-253) (Fc Tag)
-
- Target See all Interleukin 35 (IL35) Proteins
- Interleukin 35 (IL35)
- Protein Type
- Recombinant
- Protein Characteristics
- AA 21-229, AA 57-253
-
Origin
- Human
-
Source
- CHO Cells
- Purification tag / Conjugate
- This Interleukin 35 protein is labelled with Fc Tag.
- Purpose
- IL-35 (human):Fc (human) (rec.)
- Specificity
- The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1.
- Characteristics
- Protein. The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1. Source: CHO cells. Endotoxin content: <0.06EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.
- Purity
- >98 % (SDS-PAGE)
- Endotoxin Level
- <0.06EU/μg protein (LAL test, Lonza).
- Biological Activity Comment
- Bioactivity was measured in a cell proliferation assay using anti-CD3 activated human peripheral mononuclear cells.
- Top Product
- Discover our top product IL35 Protein
-
Interleukin 35 (IL35) (AA 21-229), (AA 23-219) (Active) protein (His tag)
IL35 Origin: Human Host: Escherichia coli (E. coli) > 97 % AcA, CC Active
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Concentration
- Lot specific
- Buffer
- Lyophilized from 0.2μm-filtered solution in PBS.
- Handling Advice
- Avoid freeze/thaw cycles.
- Storage
- 4 °C,-20 °C
- Storage Comment
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
-
- Target
- Interleukin 35 (IL35)
- Alternative Name
- IL-35 (IL35 Products)
- Background
-
Alternate Names/Synonyms: Interleukin-35
Product Description: Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.
- NCBI Accession
- NP_000873
-
